Heart and lung machine (ECMO) boosts survival for pregnant women with pulmonary arterial hypertension and pregnancy in a case series, Pulmonary Hypertension News, February 2, 2026

Pulmonary Hypertension News published a report on February 2, 2026, about a case series and literature review found that ECMO (extracorporeal membrane oxygenation)—a life-support machine that temporarily replaces heart and lung function—significantly improves survival in pregnant women with severe pulmonary arterial hypertension (PAH). The study documented five cases where the machine was used as rescue […]

Heart and lung machine (ECMO) boosts survival for pregnant women with pulmonary arterial hypertension and pregnancy in a case series, Pulmonary Hypertension News, February 2, 2026 Read Post »

Phase 2 PHocus trial of mosliciguat completes enrollment in pulmonary hypertension associated with interstitial lung disease PH-ILD, Pulmonary Hypertension News, February 9, 2026

The February 9 2026 edition of Pulmonary Hypertension News reports that enrollment has been completed in under a year for the PHocus Phase 2 clinical trial testing mosliciguat, a once-daily inhaled therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD)—a condition where current treatment options remain limited and often poorly tolerated. Developed by Pulmovant,

Phase 2 PHocus trial of mosliciguat completes enrollment in pulmonary hypertension associated with interstitial lung disease PH-ILD, Pulmonary Hypertension News, February 9, 2026 Read Post »

Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up, European Heart Journal, February 6, 2026

An Italian study examined whether echocardiographic patterns of right heart changes could improve risk prediction in pulmonary arterial hypertension patients beyond current tools. Researchers defined four phenotypes based on right ventricular size and function, then followed patients for nearly 4 years. They found that these echo-based classifications provided additional prognostic information independent of existing risk

Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up, European Heart Journal, February 6, 2026 Read Post »

Early pulmonary arterial hypertension diagnosis improves five-year survival, Mayo Clinic study finds, Pulmonary Hypertension News, January 7, 2026

A recent study published in Pulmonary Circulation, summarised in an article by Andrea Lob on Pulmonary Hypertension News, found that early diagnosis of pulmonary arterial hypertension (PAH) – within six months of first healthcare contact for symptoms – improves five-year survival by 42 percentage points compared to delayed diagnosis (two years or more). Five-year survival

Early pulmonary arterial hypertension diagnosis improves five-year survival, Mayo Clinic study finds, Pulmonary Hypertension News, January 7, 2026 Read Post »

Self-management in pulmonary arterial hypertension: insights from patient interviews, Patient Preference and Adherence Journal, January 17, 2026

Twelve pulmonary arterial hypertension patients followed at the Fuwai Central China Cardiovascular Hospital in Zhengzhou City in the Henan Province, China, were interviewed to understand their self-management challenges. The findings were published in the Patient Preference and Adherence Journal on January 17, 2026, and reveal significant barriers to effective disease self-management across two main categories.

Self-management in pulmonary arterial hypertension: insights from patient interviews, Patient Preference and Adherence Journal, January 17, 2026 Read Post »

Pulmonary arterial hypertension associated with exposure to toxic rapeseed oil, European Respiratory Journal Open Research, December 19, 2025

A prospective analysis from the Spanish Registry of pulmonary arterial hypertension (REHAP) examined 59 patients diagnosed with toxic oil syndrome-associated pulmonary arterial hypertension (TOS-PAH) between 1997 and 2025, providing new clinical, pathological and genetic insights into this historically significant form of drug-induced pulmonary arterial hypertension. Key findings: The patient cohort was 63% female with a

Pulmonary arterial hypertension associated with exposure to toxic rapeseed oil, European Respiratory Journal Open Research, December 19, 2025 Read Post »

The acute pulmonary vasoreactivity in pulmonary arterial hypertension revisited in the contemporary era, International Journal of Cardiology Heart and Vasculature, February 2026

During right heart catheterization (RHC), the “acute vasodilator test” offers valuable insights into pulmonary circulation by evaluating vasoreactivity. A positive result identifies a rare pulmonary arterial subtype that may benefit from long-term calcium-channel blocker therapy (the so called “responders”). A recent study re-examines the applications, criteria, and objectives of acute vasodilator testing in pulmonary hypertension

The acute pulmonary vasoreactivity in pulmonary arterial hypertension revisited in the contemporary era, International Journal of Cardiology Heart and Vasculature, February 2026 Read Post »

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026

A retrospective cohort study using data from 103 healthcare organizations compared 454 pulmonary arterial hypertension patients receiving sotatercept to 963.386 pulmonary arterial hypertension patients not receiving sotatercept. After propensity score matching to balance baseline characteristics, 346 patients per group were analyzed over an average follow-up of approximately 6-8 months. The sotatercept group demonstrated dramatically lower

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026 Read Post »

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care

Professor Marc Humbert, one of the world’s leading specialists in pulmonary arterial hypertension (PAH), has been awarded the prestigious Inserm Grand Prize in recognition of his extraordinary career dedicated to understanding and treating this life-threatening disease. Inserm is the French National Institute of Health and Medical Research. From Orphan Disease to Hope When Prof. Humbert

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care Read Post »

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025

The Pulmonary Vascular Research Institute (PVRI) GoDeep meta-registry integrates data from international pulmonary hypertension registries, from which 21,123 incident hemodynamically fully characterised patients were analysed to investigate the influence of sex on survival of patients. Findings revealed that male patients have significantly higher mortality rates than female patients across all types of pulmonary hypertension. This survival

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025 Read Post »

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025

A very interesting article by Prof. Werner Seeger recounts the discovery and development of inhaled prostanoids for pulmonary hypertension at the Giessen Pulmonary Hypertension center (Germany) in the late 1980s-1990s (§). Initially researching acute lung injury/Acute Respiratory Distress Syndrome (ARDS), researchers at Giessen observed that while intravenous vasodilators worsened ventilation/perfusion mismatch, aerosolized prostacyclin (PGI2) reduced

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025 Read Post »

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025

Parenteral prostacyclin therapy remains the cornerstone for high-risk pulmonary arterial hypertension (PAH) patients but is limited by complications and reduced quality of life. A case series of eight high-risk patients demonstrated that adding sotatercept successfully enabled transition from intravenous to oral prostacyclin therapy. All patients received background dual therapy with endothelin receptor antagonists and phosphodiesterase-5

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025 Read Post »

Merck Receives Positive EU CHMP Opinion for Expanded Use of Sotatercept in Adults with Pulmonary Arterial Hypertension, December 12, 2025

The European Medicines Agency’s Committee for Human Medicinal Products (CHMP) has recommended expanding WINREVAIR™ (sotatercept) approval for pulmonary arterial hypertension (PAH) treatment to include World Health Organisation (WHO) Functional Class II, III, and IV patients (previously only II-III). The recommendation is based on the Phase 3 ZENITH trial, which showed a 76% reduction in risk

Merck Receives Positive EU CHMP Opinion for Expanded Use of Sotatercept in Adults with Pulmonary Arterial Hypertension, December 12, 2025 Read Post »

Cereno Scientific receives Food and Drug Administration (FDA) clearance to initiate global Phase IIb clinical trial of CS1 in pulmonary arterial hypertension (PAH), December 8, 2025

The Food and Drug Administration (FDA)’s recent clearance for a Cereno Scientific Phase IIb trial on CS1 builds on the favourable safety, tolerability and encouraging disease-modifying signals observed in the Phase IIa study. CS1, an HDACi that acts through epigenetic modulation, has also been granted Orphan Drug Designation and Fast Track designation in the US. The

Cereno Scientific receives Food and Drug Administration (FDA) clearance to initiate global Phase IIb clinical trial of CS1 in pulmonary arterial hypertension (PAH), December 8, 2025 Read Post »

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025

The ASPYRE-1 study presents the baseline characteristics of patients enrolled in the national prospective registry created through the Italian Network on Pulmonary Arterial Hypertension (IPHNET). The registry was established in 2014 with the aim of better understanding the contemporary profile of Italian pulmonary arterial hypertension patients and to support future analyses on risk stratification and

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025 Read Post »

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025

A new study published recently on CHEST evaluated whether the Pulmonary Hypertension Functional Class Self-Report (PH-FC-SR)—a patient-reported version of the World Health Organisation (WHO) Functional Class—captures functional status in a way that reflects patients’ real experiences. Study Overview Eighty-nine adults with pulmonary hypertension (Groups 1–5) from the Cleveland Clinic and Mayo Clinic completed an online

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025 Read Post »

PF-07868489: Pfizer’s New Biologic Enters Phase 2 for Pulmonary Arterial Hypertension

Pfizer has a new study ongoing on PF-07868489, a recombinant human IgG1 antibody that targets bone morphogenetic protein 9 (BMP9) and is administered through subcutaneous route for the treatment of PAH. PF-07868489 is currently in Phase 2 development and has received Orphan Drug designation in the US.  The study (NCT06137742) has two parts: Part A: An

PF-07868489: Pfizer’s New Biologic Enters Phase 2 for Pulmonary Arterial Hypertension Read Post »

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025

Pulmonary veno-occlusive disease (PVOD) is a rare, severe World Health Organisation Group 1 pulmonary arterial hypertension (PAH) subtype with poor survival. pulmonary arterial hypertension-targeted vasodilators can cause life-threatening pulmonary edema in Pulmonary veno-occlusive disease, underscoring the need for diagnostic tools to distinguish it from other pulmonary arterial hypertension subtypes The findings of a study recently

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025 Read Post »

Inhibikase Therapeutics Phase 3 study on IKT-001 – an anti-proliferative tyrosine kinase inhibitor – expected to be initiated in the first quarter of 2026

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company has announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in pulmonary arterial hypertension The Phase 3 study, named IMPROVE-PAH, is expected to be initiated in the first quarter of 2026. IKT-001 is an investigational novel pro-drug of imatinib mesylate. Imatinib is

Inhibikase Therapeutics Phase 3 study on IKT-001 – an anti-proliferative tyrosine kinase inhibitor – expected to be initiated in the first quarter of 2026 Read Post »

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025

Combined post- and precapillary pulmonary hypertension (CpcPH) represents a subset of pulmonary hypertension due to left heart disease (PH-LHD), also known as World Health Organisation Group 2 pulmonary hypertension. There are currently no treatments specifically approved for this condition. The CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025 Read Post »

TRANSLATE »
Scroll to Top